Knight Therapeutics (TSE:GUD) Raised to “Strong-Buy” at Research Capitl

Research Capitl upgraded shares of Knight Therapeutics (TSE:GUD) from a hold rating to a strong-buy rating in a report issued on Tuesday morning,Zacks.com reports.

Separately, Raymond James upgraded shares of Knight Therapeutics to a “moderate buy” rating in a research note on Friday, November 15th. Two investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Strong Buy” and an average target price of C$7.08.

Knight Therapeutics Stock Performance

TSE:GUD opened at C$5.88 on Tuesday. The company has a fifty day simple moving average of C$5.58 and a two-hundred day simple moving average of C$5.56. The company has a market cap of C$594.76 million, a price-to-earnings ratio of -19.63, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The company has a quick ratio of 1.79, a current ratio of 3.36 and a debt-to-equity ratio of 7.52. Knight Therapeutics has a 52 week low of C$5.09 and a 52 week high of C$6.23.

Insider Buying and Selling

In other news, insider Sime Armoyan bought 17,600 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was purchased at an average price of C$5.48 per share, for a total transaction of C$96,488.48. Insiders own 45.62% of the company’s stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.